Φορτώνει......

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity

PURPOSE: Development of novel agents and drug combinations are urgently needed for treatment of pancreatic cancer. Oxaliplatin belongs to an important class of DNA-damaging organoplatinum agents, useful in pancreatic cancer therapy. However, increased ability of cancer cells to recognize and repair...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Melisi, Davide, Ossovskaya, Valeria, Zhu, Cihui, Rosa, Roberta, Ling, Jianhua, Dougherty, Patrick M., Sherman, Barry M., Abbruzzese, James L., Chiao, Paul J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2009
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2989607/
https://ncbi.nlm.nih.gov/pubmed/19808866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0910
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!